Piper Sandler Begins Coverage on Innoviva (NASDAQ:INVA)

Piper Sandler initiated coverage on shares of Innoviva (NASDAQ:INVA – Get Free Report) in a research note issued to investors on Wednesday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $29.00 price target on the biotechnology company’s stock. Piper Sandler‘s price target suggests a potential upside of 57.52% from the stock’s previous close.

INVA has been the subject of several other reports. Wall Street Zen cut Innoviva from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Cantor Fitzgerald dropped their target price on Innoviva from $36.00 to $34.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Weiss Ratings raised Innoviva from a “hold (c+)” rating to a “buy (b)” rating in a research note on Monday, November 9th. Oppenheimer decreased their price target on Innoviva from $35.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, November 5th. Finally, Zacks Research upgraded Innoviva from a “strong sell” rating to a “hold” rating in a report on Monday, August 31st. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.00.

Get Our Latest Research Report on Innoviva

Innoviva Stock Performance

Shares of Innoviva stock opened at $18.41 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 15.44 and a quick ratio of 14.58. The firm has a 50 day simple moving average of $20.48 and a 200 day simple moving average of $21.82. Innoviva has a fifty-two week low of $18.19 and a fifty-two week high of $25.15. The firm has a market cap of $1.31 billion, a P/E ratio of 5.30, a P/E/G ratio of 2.64 and a beta of 0.38.

Innoviva (NASDAQ:INVA – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.52 by ($1.55). The firm had revenue of $106.12 million for the quarter, compared to analyst estimates of $115.31 million. Innoviva had a return on equity of 22.91% and a net margin of 44.13%. Sell-side analysts predict that Innoviva will post 2.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Innoviva

Large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP lifted its position in shares of Innoviva by 1.7% in the first quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company’s stock valued at $103,366,000 after buying an additional 76,026 shares during the last quarter. BlackRock Inc. bought a new position in shares of Innoviva during the 2nd quarter worth approximately $77,562,000. Bank of America Corp DE bought a new position in shares of Innoviva during the 2nd quarter worth approximately $37,873,000. Deutsche Bank AG acquired a new position in shares of Innoviva during the 2nd quarter worth approximately $20,847,000. Finally, William Blair Investment Management LLC increased its holdings in shares of Innoviva by 29.7% during the 3rd quarter. William Blair Investment Management LLC now owns 832,881 shares of the biotechnology company’s stock worth $17,665,000 after acquiring an additional 190,705 shares during the last quarter. 99.12% of the stock is currently owned by institutional investors.

About Innoviva

(Get Free Report)

Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.

Further Reading

Analyst Recommendations for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.